NMC
ADAP

NEA Management Company’s Adaptimmune Therapeutics ADAP Stock Holding History

NEA Management Company’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,079,778
Closed -$4.09M – 30
2025
Q2 		$4.09M Hold
17,079,778
– – 0.31% 26
2025
Q1 		$3.36M Hold
17,079,778
– – 0.26% 30
2024
Q4 		$9.2M Hold
17,079,778
– – 0.52% 27
2024
Q3 		$16.2M Hold
17,079,778
– – 0.88% 20
2024
Q2 		$16.7M Hold
17,079,778
– – 1.25% 18
2024
Q1 		$27M Hold
17,079,778
– – 1.68% 15
2023
Q4 		$13.5M Hold
17,079,778
– – 0.9% 22
2023
Q3 		$13.3M Hold
17,079,778
– – 1.03% 22
2023
Q2 		$15.8M Sell
17,079,778
-1
-0% -$1 1.21% 23
2023
Q1 		$18.6M Hold
17,079,779
– – 1.29% 21
2022
Q4 		$24.9M Sell
17,079,779
-2,833
-0% -$4.59K 1.4% 18
2022
Q3 		$18.4M Hold
17,082,612
– – 0.92% 29
2022
Q2 		$29M Buy
17,082,612
+1
+0% +$2 1.49% 17
2022
Q1 		$35.2M Hold
17,082,611
– – 1.02% 18
2021
Q4 		$64.1M Hold
17,082,611
– – 1.29% 15
2021
Q3 		$88.3M Hold
17,082,611
– – 1.05% 13
2021
Q2 		$72.8M Hold
17,082,611
– – 0.95% 15
2021
Q1 		$90.7M Hold
17,082,611
– – 2.04% 12
2020
Q4 		$92.1M Hold
17,082,611
– – 2.43% 13
2020
Q3 		$136M Hold
17,082,611
– – 5.77% 3
2020
Q2 		$171M Hold
17,082,611
– – 6.87% 4
2020
Q1 		$46.5M Buy
17,082,611
+1,250,000
+8% +$4.15M 2.43% 15
2019
Q4 		$19M Hold
15,832,611
– – 0.9% 19
2019
Q3 		$23.9M Hold
15,832,611
– – 1.98% 15
2019
Q2 		$63.6M Hold
15,832,611
– – 4.46% 7
2019
Q1 		$68.1M Hold
15,832,611
– – 3.53% 10
2018
Q4 		$91M Hold
15,832,611
– – 3.61% 6
2018
Q3 		$215M Buy
15,832,611
+2,500,000
+19% +$26.2M 9.26% 2
2018
Q2 		$158M Hold
13,332,611
– – 7.41% 2
2018
Q1 		$150M Buy
13,332,611
+1,306,612
+11% +$11.4M 6.66% 3
2017
Q4 		$80.3M Hold
12,025,999
– – 3.33% 9
2017
Q3 		$98.5M Hold
12,025,999
– – 3.45% 6
2017
Q2 		$54M Hold
12,025,999
– – 1.96% 10
2017
Q1 		$66.3M Buy
12,025,999
+2,145,000
+22% +$9.38M 2.3% 8
2016
Q4 		$40M Hold
9,880,999
– – 1.59% 13
2016
Q3 		$69.7M Hold
9,880,999
– – 3.13% 6
2016
Q2 		$80.5M Hold
9,880,999
– – 4.18% 6
2016
Q1 		$80.3M Buy
+9,880,999
New +$80.8M 5.33% 4

Other funds holding ADAP

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

NEA Management Company's ADAP Position: Q3 2025 in Review

NEA Management Company sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 17,079,778 shares — an estimated $4.09M sold.

NEA Management Company first reported a position in ADAP in Q1 2016 and held it in 38 quarters. The position peaked at $215M in Q3 2018. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

  • NEA Management Company reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
  • NEA Management Company sold 17,079,778 Adaptimmune Therapeutics shares in Q3 2025, an estimated $4.09M.
  • NEA Management Company first reported a position in Adaptimmune Therapeutics in Q1 2016 and held it in 38 quarters.
  • NEA Management Company's Adaptimmune Therapeutics position peaked at $215M in Q3 2018.
  • 55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on NEA Management Company's 13F filing for Q3 2025, filed 14 Nov 2025.